StockNews.AI
ABBV
StockNews.AI
188 days

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

1. AbbVie collaborates with Xilio on novel immunotherapies, enhancing oncology expertise. 2. Xilio's technology could lead to innovative cancer treatments, potentially impacting AbbVie positively.

2m saved
Insight
Article

FAQ

Why Bullish?

The collaboration signals growth potential in AbbVie's oncology pipeline, similar to successful past partnerships.

How important is it?

This partnership is significant as it's focused on long-term product development and market position enhancement.

Why Long Term?

The development of new immunotherapies can create substantial revenue streams over years, similar to AbbVie's prior drug launches.

Related Companies

XLOABT
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass.

Related News